middle.news
How Neurotech Halved Losses While Advancing NTI164’s Autism and Rett Trials
8:04pm on Thursday 26th of February, 2026 AEDT
•
Healthcare
Read Story
How Neurotech Halved Losses While Advancing NTI164’s Autism and Rett Trials
8:04pm on Thursday 26th of February, 2026 AEDT
Key Points
Half-year loss narrows 91% to $696,501
Revenues double to $4.74 million driven by R&D grants
Phase 3 clinical trial for NTI164 in Autism Spectrum Disorder approved
FDA grants Rare Pediatric Disease Designation for Rett syndrome therapy
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurotech International (ASX:NTI)
OPEN ARTICLE